These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11157022

  • 1. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
    Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt PA, Stout R, Simms T, Davies R, Pettengell R.
    J Clin Oncol; 2001 Feb 01; 19(3):712-9. PubMed ID: 11157022
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N.
    J Natl Cancer Inst; 2005 May 04; 97(9):666-74. PubMed ID: 15870437
    [Abstract] [Full Text] [Related]

  • 3. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.
    Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG.
    J Clin Oncol; 1995 Jan 04; 13(1):148-56. PubMed ID: 7528271
    [Abstract] [Full Text] [Related]

  • 4. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis.
    Buchholz E, Manegold C, Pilz L, Thatcher N, Drings P.
    J Thorac Oncol; 2007 Jan 04; 2(1):51-8. PubMed ID: 17410010
    [Abstract] [Full Text] [Related]

  • 5. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 04; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 6. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
    Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M.
    J Clin Oncol; 1999 Nov 04; 17(11):3531-9. PubMed ID: 10550151
    [Abstract] [Full Text] [Related]

  • 7. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):533-41. PubMed ID: 18398095
    [Abstract] [Full Text] [Related]

  • 8. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar 16; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 9. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 16; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 10. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE.
    Oncology; 1997 Feb 16; 54(5):363-70. PubMed ID: 9260596
    [Abstract] [Full Text] [Related]

  • 11. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
    Iwasaki Y, Nagata K, Nakanishi M, Natuhara A, Kubota Y, Ueda M, Arimoto T, Hara H.
    Chest; 2005 Oct 16; 128(4):2268-73. PubMed ID: 16236883
    [Abstract] [Full Text] [Related]

  • 12. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C, European Organization for Research and Treatment of Cancer-Lung Cancer Group.
    J Clin Oncol; 2002 Oct 01; 20(19):3947-55. PubMed ID: 12351591
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S.
    J Med Assoc Thai; 2000 May 01; 83(5):549-53. PubMed ID: 10863902
    [Abstract] [Full Text] [Related]

  • 14. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.
    Bone Marrow Transplant; 2000 Jan 01; 25(1):5-11. PubMed ID: 10654007
    [Abstract] [Full Text] [Related]

  • 15. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G, Tetef M.
    J Clin Oncol; 1996 Oct 01; 14(10):2631-7. PubMed ID: 8874321
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
    Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ.
    J Clin Oncol; 2005 Nov 20; 23(33):8371-9. PubMed ID: 16293867
    [Abstract] [Full Text] [Related]

  • 17. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
    Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S.
    Int J Radiat Oncol Biol Phys; 1998 Jan 15; 40(2):331-6. PubMed ID: 9457817
    [Abstract] [Full Text] [Related]

  • 18. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Samantas E, Pectasides D, Pavlidis N, Kalofonos C, Klouvas G, Panoussaki E, Tsiakopoulos E, Poulakis N, Fountzilas G.
    Am J Clin Oncol; 1999 Feb 15; 22(1):87-93. PubMed ID: 10025390
    [Abstract] [Full Text] [Related]

  • 19. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U.
    Am J Clin Oncol; 2009 Feb 15; 32(1):61-4. PubMed ID: 19194127
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH.
    J Clin Oncol; 1995 Jul 15; 13(7):1615-22. PubMed ID: 7602350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.